"PADIS"- Pain, Agitation/Sedation, Delirium, Immobility, Sleep

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/88

encourage image

There's no tags or description

Looks like no tags are added yet.

89 Terms

1
New cards

unpleasant sensory and emotional experience associated with actual or potential tissue damage

pain

2
New cards

condition characterized by apprehension, increased motor activity, and autonomic arousal

state of anxiety accompanied by motor restlessness

agitation

3
New cards

syndrome characterized by acute cerebral dysfunction with a change or fluctuation in baseline mental status

disturbed level of consciousness and change in cognition OR development of a perceptual disturbance

delirium

4
New cards

what is an issue with pain management in ICU patients

may be unable to self report pain

5
New cards

pain related stress response

increases sympathetic nervous system activation, vasoconstriction, impaired wound healing, alter breathing patterns

6
New cards

gold standard of monitoring pain

patient self reporting

7
New cards

what to use if a patient is unable to self report pain

behavioral pain scale (BPS), critical care pain observation tool (CPOT)- uses facial expression and body movements

8
New cards

preferred method for preemptive analgesia in non-neuropathic pain

IV opioids

9
New cards

feature of opioids that must be considered

may have sedative effects

10
New cards

what to use to decrease opioid requirements

non-opioid analgesics (acetaminophen, neuropathic pain meds, ketamine, MAYBE NSAIDs)

11
New cards

frequent in critically ill patients, associated with adverse clinical outcomes and examples

agitation- ventilator dysynchrony (difficult to mechanically ventilate), physical aggression, increased motor activity

12
New cards

underlying causes of agitation

pain

mechanical ventilation

delirium

hypoxia

hypotension

withdrawal

13
New cards

non pharm treatment of agitation

patient comfort, adequate analgesia, normal sleep

14
New cards

required by most patients with mechanical ventilation

pharmacological sedation

15
New cards

the act of calming, by the administration of a sedative drug

mainstay for treatment of agitation/anxiety in ICU

sedation

16
New cards

state of minimal motor activity that is physically similar to sleep, artificially induced

hypnosis

17
New cards

reduction of emotional and physical responses to real/ perceived danger

anxiolysis

18
New cards

when to start pharmacological sedation

after providing adequate analgesia and treating reversible physiological causes

19
New cards

what to NOT use sedation for

method of restraint, coercion, discipline

20
New cards

what occurs with over sedation

increased time on mechanical ventilation, increased ICU stay time, obscure neurological function testing

21
New cards

best plan with sedation

LESS IS BEST

22
New cards

how to achieve light sedation

daily sedation interruption, nursing protocolized targeted sedation to facilitate titration of sedatives

23
New cards

subjective assessment options for sedation and when can these not be used

RASS and SAS, difficult in patients with altered level of mentation

24
New cards

objective assessment of sedation

bispectral index (BIS), scale of 100 (completely awake) to 0 (isoelectric EEG)

25
New cards

who is EEG monitoring recommended for

non-convulsive seizure activity in ICU patients and patients whom other measures are not feasible (deep sedation or neuromuscular blockade)

26
New cards

ideal sedative agent

rapid onset, minimal respiratory depression, no drug interactions, no tolerance, inexpensive, does not contribute to delirium

27
New cards

sedative drugs used in the ICU

BZDs, propofol, dexmedetomidine

28
New cards

MOA of BZDs

Binds to a specific site on GABA (a) receptors, enhances GABA-mediated neuronal inhibition

29
New cards

primary BZDs used for sedation in ICU

lorazepam, midazolam

30
New cards

adverse effects of BZDs

respiratory depression, CV effects, withdrawal, delayed emergence from sedation, potential delirium association

31
New cards

when can BZD withdrawal occur, what happens during withdrawal, and how to prevent it

with abrupt discontinuation, risk of seizures, gradual tapering is required

32
New cards

what increases a patient's risk of having delayed emergence from sedation with BZDs

prolonged infusion, advanced age, hepatic/renal insufficiency

33
New cards

specific BZD that is affected by hepatic/ renal insufficiency

midazolam

34
New cards

preferred route of administration for lorazepam

IV preferred

35
New cards

onset/ duration of action of lorazepam and why

least lipid soluble, delayed onset and prolonged duration of effect

36
New cards

why is lorazepam not expected to accumulate in the elderly

metabolized into inactive metabolite by glucuronidation

37
New cards

consequences of propylene glycol (PG) solvent in IV formulations of lorazepam

potential lactic acidosis, nephrotoxicity after high doses or prolonged infusions

38
New cards

what to monitor if concerned about PG concentrations with lorazepam, what value may indicate potential toxicity

osmol gap, >10

39
New cards

why is lorazepam not the best choice if rapid awakening is required

intermediate half life

40
New cards

onset of midazolam and why

increased lipid solubility, rapid onset

41
New cards

how is midazolam metabolized and what increases the half life

hepatically metabolized by CYP4503A, t1/2 increased in elderly, hepatic disease, numerous drug interactions

42
New cards

what causes prolonged/ unpredictable effects of midazolam and why

prolonged use- can lead to metabolite accumulation

43
New cards

what type of use is midazolam recommended for

short term use (<48 hours) for shorter awakening times

44
New cards

alkylphenol sedative and hypnotic agent with rapid onset and rapid offset

propofol

45
New cards

why is propofol growing popularity for procedural sedation

very titratable

46
New cards

metabolism and Vd of propofol

hepatically metabolized, highly protein bound with large Vd

47
New cards

what patient population is propofol used in and why

neurosurgical patients, reduces ICP and rapid resolution of sedative effects following d/c

48
New cards

why do you need to account for propofol in nutritional assessments

it is an emulsion in a phospholipid vehicle that provides 1.1 kcal/mL

49
New cards

result of long term infusion of propofol and monitoring

hypertriglyceridemia, check TGs following 48h of treatment and periodically thereafter

50
New cards

max hang length for propofol

12 hours

51
New cards

most important adverse effect of propofol and common features

propofol infusion syndrome (acidosis, bradycardia, lipidemia)

52
New cards

risk factors of propofol infusion syndrome

sustained treatment (>48 hours), high doses (>75 ug/kg/min)

53
New cards

monitoring to watch out for propofol infusion syndrome

TGs, CK, LFTs, metabolic acidosis, bradycardia, hypotension

54
New cards

preservatives in propofol that may cause ADRs

EDTA, sodium metabisulfate, benzyl alcohol and benzyl alcohol/sodium benzoate

55
New cards

what can occur from EDTA in Diprivan

electrolyte abnormalities after >7 days of treatment

56
New cards

what patients have a greater risk of allergic reactions to sodium metabisulfate in propofol

allergic reactions

57
New cards

how to avoid withdrawal from propofol

gradual tapering of dose esp if >7 days of therapy

58
New cards

when is propofol the preferred sedative and what is it widely used for

when rapid awakening is important and in neurotrauma, widely use in procedural sedation

59
New cards

selective a2 agonist that inhibits excitatory neurotransmitters

dexmedetomidine

60
New cards

what is different about sedation from dexmedetomidine compared to other agents

patients readily arousable with gentle stimulation, analgesic sparing effects, no respiratory depression

61
New cards

when to not use dexmedetomidine

when deep sedation is required

62
New cards

t1/2 and metabolism of dexmedetomidine

short half life, hepatically metabolized

63
New cards

how is dexmedetomidine dose changed in hepatic dysfunction

decrease dose by 40-70%

64
New cards

what dosing is recommended by the dexmedetomidine PI that is not actually followed and why

loading infusion over 10-20 minutes, it increases CV effects

65
New cards

how to administer dexmedetomidine loading infusion to avoid CV effects

administer over longer time (>30 minutes) or with lower loading dose

66
New cards

main adverse effects seen with dexmedetomidine and what patients are most likely to experience this

bradycardia and hypotension, more seen in volume depleted patients or patients with increased sympathetic tone

67
New cards

what patients should dexmedetomidine not be used in

hemodynamic instability/ high sympathetic tone

68
New cards

when is dexmedetomidine use recommended over propfol

in mechanically ventilated ICU patients where light sedation and/or delirium reduction are priortized

69
New cards

cardinal features of delirium

decreased clarity of awareness of environment with a reduced ability to focus AND either a change in cognition or development of a perpetual disturbance

70
New cards

2 subtypes of delirium and which is often misdiagnosed

hyperactive (agitated)

hypoactive (calm/lethargic)- often misdiagnosed

71
New cards

what occurs with longer duration of delirium

greater chance for prolonged and irreversible impairment, associated with increased length of ICU stay and potentially mortality

72
New cards

modifiable risks for delirium

BZDs and blood transfusions + prolonged physical restraint or immobility

73
New cards

assessment tools to assess delirium

ICDSC or CAM-ICU

74
New cards

nonpharm delirium treatment

reduce environmental causes, early mobilization, optimization of sleep, optimization of hearing and vision

75
New cards

when is pharmacological treatment not recommended for delirium

prevention

76
New cards

may be used short term for treatment of delirium associated with significant stress

antipsychotics (haloperidol or atypical antipsychotics)

77
New cards

recommended for delirium where agitation is precluding weaning of vent/ extubation and why

dexmedetomidine because it does not cause respiratory depression

78
New cards

antipsychotic with mild sedation without analgesia or amnesia

haloperidol

79
New cards

main adverse effect of haloperidol

prolongation of QT interval on ECG, potential TdP

80
New cards

when to d/c haloperidol due to TdP risk

if Qtc exceeds 450 msec or increases >25% from baseline

81
New cards

other adverse effects of haloperidol

decreases seizure threshold, possible EPS, neuroleptic malignant syndrome (NMS)

82
New cards

what are the atypical antipsychotics and why are they potentially preferred over haloperidol

risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone

less adverse effects (QTc prolongation/EPS)

83
New cards

which atypical antipsychotic has the highest rate of prolonged QTc interval

ziprasidone

84
New cards

which atypical antipsychotic is associated with NMS

olanzapine

85
New cards

sedation guidelines

less is more, sedation should only be used if required, goal is calm but arousable patient

86
New cards

measures that encourage light sedation

daily interruption of sedative infusions with retitration

nursing-protocolized targeted sedation

87
New cards

what is recommended to be trialed first when it comes to sedation and why

analgesia first sedation recommended, pain is often primary source of agitation

88
New cards

which sedative agents are least preferred

BZDs

89
New cards

preferred sedative when rapid awakening is desired or in neurotrauma

propofol